AGILE GROUP (03383) reported a total presale amount of approximately 4.29 billion yuan for the first seven months, a decrease of 24.6% compared to the same period last year.
Aquila Group (03383) announced that the pre-sale amount for the company and its subsidiaries (the Group), along with the Group's joint ventures and associates, as well as real estate projects managed by the Group and sold under the "Aquila" brand (Aquila projects), is approximately RMB 490 million as of July 2026, corresponding to a construction area of about 66,000 square meters; the average price is RMB 7,358 per square meter.
AGILE GROUP (03383) announced that the total presale amount of the company and its subsidiaries (the Group), along with the Group's joint ventures and associates, as well as real estate projects managed by the Group and sold under the "Aojiale" brand (Aojiale Projects) in July 2026 is approximately RMB 490 million, corresponding to a gross floor area of about 66,000 square meters; the average price is RMB 7,358 per square meter.
For the seven months ending July 31, 2026, the total presale amount of the Group, together with the Group's joint ventures and associates, and the Aojiale Projects is approximately RMB 4.29 billion, representing a year-on-year decrease of 24.6%, corresponding to a gross floor area of about 474,000 square meters; the average price is RMB 9,049 per square meter.
Related Articles

ASCLETIS-B (01672) announced that its GLP-1 oral small molecule ASC30 has launched global Phase III clinical studies and released positive preclinical data for its first-in-class oral small molecule GLP-1/GIP/insulin fixed-dose combination formulation.

Porton Pharma Solutions (300363.SZ) subsidiary obtains drug manufacturing license.

Luxshare Precision Industry (02475): As of the end of July, a total of 17.665 million A-shares have been repurchased.
ASCLETIS-B (01672) announced that its GLP-1 oral small molecule ASC30 has launched global Phase III clinical studies and released positive preclinical data for its first-in-class oral small molecule GLP-1/GIP/insulin fixed-dose combination formulation.

Porton Pharma Solutions (300363.SZ) subsidiary obtains drug manufacturing license.

Luxshare Precision Industry (02475): As of the end of July, a total of 17.665 million A-shares have been repurchased.

RECOMMEND





